Sixfold Bioscience, an RNA delivery company, today announced their upcoming presentation at the 10th Oligonucleotide Networking Event in Basel.
The event will see speakers from Novartis, Cytiva, GSK, Roche, AstraZeneca, Janssen, BioMax, Ionis, Biogen and Sixfold converge at the Novartis campus in Basel for two days, from Tuesday 28th to Wednesday 29th of March, 2023.
Sixfold Bioscience founder and co-CEO Dr. Perdrix Rosell will be presenting her talk on “‘RNA to deliver RNA’ – programmable delivery systems for targeted non-hepatic delivery” at 14:45 pm CET on Tuesday 28th.
This years’ theme is "Continuing Excellence in Oligo Development - Maximizing Healthcare Benefits" and will feature talks on:
Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company, founded in 2017, based at the Translation & Innovation Hub in White City, London. Sixfold develops programmable drug delivery systems, with a current focus on siRNA and ASO.
Sixfold’s RNA delivery platform, Mergo®, was conceived by co-founders Dr Perdrix Rosell and Dr George Foot, who were left frustrated by current delivery systems that were either too toxic or faced complex engineering challenges. The Company’s differentiated approach is based on engineering biocompatible nano-architectures with precise chemical profiles that guide the RNA to selected organs.
UK pumps £13M into wide-ranging group of manufacturing projects
August 22, 2023Read more
Sixfold Bioscience Announces Formation of Scientific Advisory Board
August 9, 2023Read more
Sixfold Bioscience joins UK biotech leaders in Parliament
July 5, 2023Read more
A revolution in targeted RNA delivery [Nature Biopharma]
June 1, 2023Read more